PAVmed Inc. (PAVM) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001624326 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | $33,000 | $-5.4M | $-0.87 | Filing |
| Mar 31, 2026 | May 15, 2026 | $22,000 | $-60,000 | $-4.42 | Filing |
| Dec 31, 2025 | Mar 30, 2026 | $52,000 | $-5.4M | $6.64 | Filing |
| Sep 30, 2025 | Nov 13, 2025 | $5,000 | $-5.4M | $-0.29 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | $6,000 | $-11.9M | $-22.08 | Filing |
| Mar 31, 2025 | May 15, 2025 | $8,000 | $19.0M | $10.10 | Filing |
| Dec 31, 2024 | Mar 25, 2025 | $10,000 | $-6.4M | $17.27 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | $996,000 | $64.4M | $1.44 | Filing |
What would PAVmed Inc. have to report for its valuation to change?
At $2.41, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -27.9% a year, to $0.21. On that path the next quarter needs diluted EPS near $-0.21, against $-0.29 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -27.9% | -27.9% |
| EPS needed in final year | $0.21 | $0.21 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PAVM goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.